Immune checkpoint inhibitors

Avelumab. Avelumab, an antibody targeting programmed death-ligand 1 (PD-L1), was studied alone or in combination with pegylated liposomal doxorubicin chemotherapy followed by chemotherapy alone in patients with platinum-resistant or refractory ovarian cancer.[77] Evidence (avelumab):

Avelumab. Avelumab, an antibody targeting programmed death-ligand 1 (PD-L1), was studied alone or in combination with pegylated liposomal doxorubicin chemotherapy followed by chemotherapy alone in patients with platinum-resistant or refractory ovarian cancer.[77] Evidence (avelumab):

The JAVELIN Ovarian 200 trial (NCT02580058) accrued 556 patients between January 2016 and March 2016. Patients were randomly assigned to receive either avelumab plus pegylated liposomal doxorubicin, pegylated liposomal doxorubicin alone, or avelumab alone.[77] This study began before the FDA approved the combination of bevacizumab and pegylated liposomal doxorubicin from the AURELIA trial.[68]

Avelumab. Avelumab, an antibody targeting programmed death-ligand 1 (PD-L1), was studied alone or in combination with pegylated liposomal doxorubicin chemotherapy followed by chemotherapy alone in patients with platinum-resistant or refractory ovarian cancer.[77] Evidence (avelumab): › The JAVELIN Ovarian 200 trial (NCT02580058) accrued 556 patients between January 2016 and March 2016. Patients were randomly assigned to receive either avelumab plus pegylated liposomal doxorubicin, pegylated liposomal doxorubicin alone, or avelumab alone.[77] This study began before the FDA approved the combination of bevacizumab and pegylated liposomal doxorubicin from the AURELIA trial.[68]

The PFS and OS results failed to show superiority for avelumab over pegylated liposomal doxorubicin. The median PFS was 3.7 months (95% CI, 3.3–5.1) for patients who received the combination therapy, 3.5 months (2.1–4.0) for patients who received pegylated liposomal doxorubicin alone, and 1.9 months (1.8–1.9) for patients who received avelumab alone. The median OS was 15.7 months (95% CI, 12.7–18.7) for patients who received the combination therapy, 13.1 months (11.8–15.5) for patients who received pegylated liposomal doxorubicin alone, and 11.8 months (8.9–14.1) for patients who received avelumab alone.

Durvalumab. Early phase studies have evaluated the use of other immune checkpoint inhibitors (e.g., durvalumab) with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent disease.[78] Evidence (durvalumab):

Durvalumab. Early phase studies have evaluated the use of other immune checkpoint inhibitors (e.g., durvalumab) with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent disease.[78] Evidence (durvalumab):

In a phase I/II trial (NCT02431559), published in abstract form, 40 patients scheduled to receive pegylated liposomal doxorubicin also received durvalumab.[78]

Durvalumab. Early phase studies have evaluated the use of other immune checkpoint inhibitors (e.g., durvalumab) with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent disease.[78] Evidence (durvalumab): › In a phase I/II trial (NCT02431559), published in abstract form, 40 patients scheduled to receive pegylated liposomal doxorubicin also received durvalumab.[78]

At 6 months, the PFS rate was 47.7% (when assessed per protocol).

Durvalumab. Early phase studies have evaluated the use of other immune checkpoint inhibitors (e.g., durvalumab) with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent disease.[78] Evidence (durvalumab): › In a phase I/II trial (NCT02431559), published in abstract form, 40 patients scheduled to receive pegylated liposomal doxorubicin also received durvalumab.[78]

The overall response rate was 22.5%, with four patients achieving a complete response and five patients achieving a partial response. The median PFS was 5.5 months (0.3–28.8+) and the median OS was 17.6 months (1.7–23.5+).